Urinary Incontinence - Pipeline Review, H2 2020

July 2020 | 80 pages | ID: U76CE9897D1EN
Global Markets Direct

Abstracts

Urinary Incontinence - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Urinary Incontinence - Pipeline Review, H2 2020, provides an overview of the Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline landscape.
Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Urinary Incontinence - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 5, 3 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Urinary Incontinence (Genito Urinary System And Sex Hormones).
• The pipeline guide reviews pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Urinary Incontinence (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Urinary Incontinence (Genito Urinary System And Sex Hormones)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Urinary Incontinence (Genito Urinary System And Sex Hormones).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Urinary Incontinence (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Urinary Incontinence - Overview
Urinary Incontinence - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Urinary Incontinence - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Urinary Incontinence - Companies Involved in Therapeutics Development
Allergan Ltd
Cook MyoSite Inc
Crystec Ltd
FemmePharma Global Healthcare Inc
Innovacell Biotechnologie AG
Ixaltis
Johnson & Johnson
Ningbo Xijian Pharmaceutical Technology Co Ltd
Outpost Medicine Ltd
Pfizer Inc
Profem GmbH
Revance Therapeutics Inc
Saniona AB
Taiho Pharmaceutical Co Ltd
Urinary Incontinence - Drug Profiles
Cell Therapy for Gastrointestinal Disorders, Ischemic Heart Failure and Urological Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Urinary Incontinence - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Urinary Incontinence - Dormant Projects
Urinary Incontinence - Discontinued Products
Urinary Incontinence - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Urinary Incontinence, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Urinary Incontinence - Pipeline by Allergan Ltd, H2 2020
Urinary Incontinence - Pipeline by Cook MyoSite Inc, H2 2020
Urinary Incontinence - Pipeline by Crystec Ltd, H2 2020
Urinary Incontinence - Pipeline by FemmePharma Global Healthcare Inc, H2 2020
Urinary Incontinence - Pipeline by Innovacell Biotechnologie AG, H2 2020
Urinary Incontinence - Pipeline by Ixaltis, H2 2020
Urinary Incontinence - Pipeline by Johnson & Johnson, H2 2020
Urinary Incontinence - Pipeline by Ningbo Xijian Pharmaceutical Technology Co Ltd, H2 2020
Urinary Incontinence - Pipeline by Outpost Medicine Ltd, H2 2020
Urinary Incontinence - Pipeline by Pfizer Inc, H2 2020
Urinary Incontinence - Pipeline by Profem GmbH, H2 2020
Urinary Incontinence - Pipeline by Revance Therapeutics Inc, H2 2020
Urinary Incontinence - Pipeline by Saniona AB, H2 2020
Urinary Incontinence - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2020
Urinary Incontinence - Dormant Projects, H2 2020
Urinary Incontinence - Dormant Projects, H2 2020 (Contd..1), H2 2020
Urinary Incontinence - Dormant Projects, H2 2020 (Contd..2), H2 2020
Urinary Incontinence - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Urinary Incontinence, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Allergan Ltd
Cook MyoSite Inc
Crystec Ltd
FemmePharma Global Healthcare Inc
Innovacell Biotechnologie AG
Ixaltis
Johnson & Johnson
Ningbo Xijian Pharmaceutical Technology Co Ltd
Outpost Medicine Ltd
Pfizer Inc
Profem GmbH
Revance Therapeutics Inc
Saniona AB
Taiho Pharmaceutical Co Ltd